Why Is Wegovy Approved for Weight Loss and Not Ozempic?

Last reviewed: June 23, 2026

Last updated: June 23, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Wegovy and Ozempic are both semaglutide products manufactured by Novo Nordisk, yet only Wegovy carries FDA approval for weight loss treatment. This distinction stems not from differences in the active ingredient—both contain the same GLP-1 receptor agonist—but from separate regulatory pathways and clinical trial designs submitted to the FDA. Understanding this approval difference helps patients make informed decisions about their weight management options.

The FDA Approval Timeline and Regulatory Pathways

Ozempic entered the U.S. market in 2017 with FDA approval specifically for type 2 diabetes management. The clinical trials supporting Ozempic's approval focused on glycemic control and cardiovascular outcomes in diabetic patients, not weight loss as a primary endpoint. When Novo Nordisk sought to market semaglutide for weight management, they submitted separate clinical data through an independent approval process, resulting in Wegovy's FDA authorization in 2021.

This regulatory separation reflects how the FDA evaluates medications. A drug approved for one condition requires additional clinical evidence and a new application to gain approval for a different therapeutic use. Wegovy's approval pathway included the STEP trial series, which specifically measured weight reduction in non-diabetic and diabetic adults with obesity. The distinction ensures that patients using Wegovy receive a product with labeling that explicitly supports weight loss as its primary indication.

How Semaglutide Works in Weight Loss vs Diabetes Control

Semaglutide functions as a glucagon-like peptide-1 (GLP-1) receptor agonist, activating receptors throughout the brain and gastrointestinal system. When used for diabetes, the medication's primary benefit is reducing blood sugar by stimulating insulin secretion and slowing gastric emptying. Weight loss occurs as a secondary effect in some diabetic patients, but it is not the treatment goal. Wegovy's clinical trials, by contrast, enrolled participants and measured weight reduction as the primary outcome, demonstrating an average 15% body weight reduction over 68 weeks in the STEP 3 trial.

The same biochemical mechanism—GLP-1 receptor activation—produces both metabolic improvements and appetite suppression. In diabetic patients taking Ozempic, weight loss may be an unintended benefit. In Wegovy-prescribed patients, weight reduction is the intended therapeutic target, supported by clinical evidence specifically designed to prove efficacy for this purpose.

Why Doctors Prescribe Ozempic Off-Label for Weight Loss

Physicians can legally prescribe FDA-approved medications for conditions outside their labeled indication—a practice called off-label prescribing. Since Ozempic and Wegovy contain identical semaglutide at similar doses, many doctors have prescribed Ozempic for weight loss, particularly before Wegovy became widely available. This off-label use is medically sound when based on clinical evidence and patient need, but it operates outside the medication's official FDA-approved purpose.

The rise in Ozempic prescriptions for weight loss created supply shortages for diabetic patients who depend on the medication for glucose management. This public health concern prompted healthcare providers and the American Medical Association to encourage use of Wegovy for weight loss, reserving Ozempic supplies for diabetes treatment. PlexusDx addresses access challenges by providing compounded semaglutide injection—identical in mechanism and efficacy to both Wegovy and Ozempic—at $149 per month, without insurance requirements or membership fees.

Compounded Semaglutide as an Alternative to Branded GLP-1s

Compounded medications are prepared by licensed 503A pharmacies under strict quality standards, using FDA-approved ingredients and pharmaceutical-grade equipment. PlexusDx partners exclusively with licensed 503A compounding pharmacies to deliver semaglutide injections that function identically to Wegovy and Ozempic. Compounding allows for flexible dosing, personalized treatment adjustments, and significantly lower costs—PlexusDx semaglutide injection begins at $149 monthly across all commitment tiers, with no flat per-compound pricing increases.

Patients choosing compounded semaglutide through PlexusDx receive the same active ingredient as Wegovy users, along with medical oversight and adherence support. The service operates nationwide, accepts HSA and FSA funds, and requires no insurance. For patients seeking FDA-approved branded options, Wegovy remains the labeled choice; for those prioritizing access and affordability, compounded semaglutide delivers equivalent clinical outcomes at a fraction of the cost.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Can I use Ozempic for weight loss if my doctor prescribes it?

Yes, doctors can legally prescribe Ozempic off-label for weight loss because it contains semaglutide, the same active ingredient as Wegovy. However, Wegovy carries FDA approval specifically for weight management, making it the labeled option. PlexusDx offers compounded semaglutide as an affordable alternative, starting at $149/month, providing the identical mechanism and clinical benefit.

Is there a clinical difference between Wegovy and compounded semaglutide?

No meaningful clinical difference exists. Wegovy and PlexusDx compounded semaglutide contain the same active ingredient, semaglutide, and work through identical GLP-1 receptor activation. The primary differences are regulatory approval labeling, manufacturing location, and price—PlexusDx compounded semaglutide costs $149/month versus Wegovy's substantially higher branded price.

Why does PlexusDx use 503A compounding pharmacies instead of branded medications?

Licensed 503A compounding pharmacies meet rigorous FDA oversight standards and allow PlexusDx to provide personalized, flexible dosing at significantly lower costs than branded Wegovy or Ozempic. This approach maintains clinical equivalence while improving patient access—no insurance required, HSA/FSA eligible, and available nationwide.

What side effects should I expect from semaglutide for weight loss?

Common side effects include nausea, vomiting, diarrhea, and constipation, typically mild and diminishing over 4-8 weeks as the body adjusts. Serious side effects are rare but include pancreatitis and gallbladder issues. PlexusDx medical providers monitor all patients for adverse effects and adjust dosing to minimize symptoms while maintaining efficacy.

Can PlexusDx Precision Peptide Genetic Test predict my response to semaglutide?

Yes. PlexusDx's $99 Precision Peptide Genetic Test analyzes key variants including GLP1R rs6923761 and GIPR rs1800437, mapping 14 pathways and 49 peptides to predict individual semaglutide response. This genetic insight helps personalize your treatment plan, optimizing efficacy and minimizing side effects from the start.

Related Reading

• Wegovy For Weight Loss 2
• Ozempic For Weight Loss 2
• Average Weight Loss On Ozempic
• Wegovy Weight Loss Pills

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.